3D bioprinting technology company Aspect Biosystems has announced a collaboration with Maastricht University (UM) in the Netherlands. The focus of their project is to develop viable kidney tissue for medical testing.
Placing its RX1 bioprinter at Professor Lorenzo Moroni’s Lab, Aspect will be working with the Institute for Technology-Inspired Regenerative Medicine (MERLN) at UM.
Tamer Mohamed, President and CEO of Aspect Biosystems, explains, “Patients on life-saving, but onerous, dialysis treatments are often found waiting for donor organs that are severely limited in supply. Tissue engineers recognize the potential of their work to alleviate this problem, but kidney tissue is complex and extremely challenging to create.”
“By combining the deep expertise at MERLN with our microfluidic 3D printing technology, we are increasing our capacity to tackle these kidney-related challenges head-on.”
Creating all aspects of human tissues
Aspect Biosystems is a privately held biotechnology company founded in 2013. The company’s aim is to create human tissues on demand, and in its latest collaboration with UM, it is working further to fulfil this goal.
Mohamed explains that “At Aspect, we are committed to collaborating with leading research groups in tissue engineering and regenerative medicine to realize the broad applicability of our technology,”
The Aspect RX1 Bioprinter facilitates the fabrication of 3D tissues using the Lab-on-a-Printer™ platform, Aspect’s core technology powered by microfluidics. The Lab-on-a-Printer™ platform has printheads containing microscopic channels for the redirection of multiple fluids and inks at a time. With this capability, the technology enables the layering of multiple cell types to create 3D tissue structures.
The MERLN Institute
MERLN combines research with training an interdisciplinary generation of scientists in the field of biomedical engineering. It specializes in the fabrication of devices for cell based tissue regeneration.
The institute has been working on kidney bioprinting for 3 years, and has now developed new bioinks to help maintain and regenerate the health of kidney cells during the bioprinting process.
MERLN uses extrusion, droplet-on-demand and microfluidics to develop tissue implants and organ models, and has already developed constructs for long bone defects. Dr. Carlos Mota, head of bioprinting research and assistant professor at MERLN, will be leading the project into developing kidney tissue using 3D bioprinting technology.
The institute will be working with Aspect to 3D bioprint kidney tissue at The Moroni Lab, a research group specializing in biofabrication technologies. The group was founded in 2009 at the University of Twente, the Netherlands, and is a part of the MERLN institute at UM.
“This is an exciting opportunity,” says Prof. Moroni and Dr. Mota. “We already took our first steps in kidney tissue models and we are particularly excited to apply our expertise with Aspect’s platform technology and join forces with their innovative team, which we expect will accelerate our findings and impact in this space.”
Aspect has an option to further develop and commercialize products based upon the results of the research.
Other companies operating within the same area as Aspect Biosystems include Organovo, that already has its ExVive™ Human Kidney material on the market, and Collplant, which provides collagen biomaterials.
Impressed by Aspect’s application of 3D bioprinting? Make your nominations in the upcoming 2019 3D Printing Industry Awards.
Find 3D Printing Jobs near you now to start your career in additive manufacturing.
Featured image shows Aspect’s 3D bioprinter in action. Photo via Aspect Biosystems.